Literature DB >> 24487564

There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.

P R Lowenstein1, Viveka Nand Yadav2, Peter Chockley2, Maria Castro2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24487564      PMCID： PMC3918918          DOI： 10.1038/mt.2013.297

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

1.  Erythropoietin gene therapy leads to autoimmune anemia in macaques.

Authors:  Guangping Gao; Corinna Lebherz; Daniel J Weiner; Rebecca Grant; Roberto Calcedo; Beth McCullough; Adam Bagg; Yi Zhang; James M Wilson
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

2.  Autoimmune anemia in macaques following erythropoietin gene therapy.

Authors:  Pierre Chenuaud; Thibaut Larcher; Joseph E Rabinowitz; Nathalie Provost; Yan Cherel; Nicole Casadevall; Richard J Samulski; Philippe Moullier
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

Review 3.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 4.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Authors:  Pedro R Lowenstein; Ronald J Mandel; Wei-Dong Xiong; Kurt Kroeger; Maria G Castro
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

5.  One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

Authors:  Carlos Barcia; Maximiliano Jimenez-Dalmaroni; Kurt M Kroeger; Mariana Puntel; Alison J Rapaport; Daniel Larocque; Gwendalyn D King; Stephen A Johnson; Chunyan Liu; Weidong Xiong; Marianela Candolfi; Sonali Mondkar; Philip Ng; Donna Palmer; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2007-09-25       Impact factor: 11.454

Review 6.  Gene therapy for Parkinson's disease: from non-human primates to humans.

Authors:  Massimo S Fiandaca; Krystof S Bankiewicz
Journal:  Curr Opin Mol Ther       Date:  2010-10

Review 7.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

8.  Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

Authors:  Agnieszka Ciesielska; Piotr Hadaczek; Gabriele Mittermeyer; Shangzhen Zhou; J Fraser Wright; Krystof S Bankiewicz; John Forsayeth
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

Review 9.  Trophic factor gene therapy for Parkinson's disease.

Authors:  Jeffrey H Kordower; Anders Bjorklund
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

10.  Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.

Authors:  Weidong Xiong; Marianela Candolfi; Kurt M Kroeger; Mariana Puntel; Sonali Mondkar; Daniel Larocque; Chunyan Liu; James F Curtin; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2008-01-08       Impact factor: 11.454
View more
  2 in total

Review 1.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

2.  Impact of age and vector construct on striatal and nigral transgene expression.

Authors:  Nicole K Polinski; Fredric P Manfredsson; Matthew J Benskey; D Luke Fischer; Christopher J Kemp; Kathy Steece-Collier; Ivette M Sandoval; Katrina L Paumier; Caryl E Sortwell
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-07       Impact factor: 6.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.